FY2025 EPS Estimates for Urogen Pharma Increased by Analyst

Urogen Pharma (NASDAQ:URGN) – Analysts at HC Wainwright increased their FY2025 earnings per share estimates for shares of Urogen Pharma in a report released on Monday, November 10th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($3.34) per share for the year, up from their previous estimate of ($3.37). HC Wainwright currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q4 2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.42) EPS and Q3 2026 earnings at ($0.14) EPS.

URGN has been the topic of a number of other research reports. Piper Sandler began coverage on shares of Urogen Pharma in a report on Monday, August 18th. They issued an “overweight” rating and a $36.00 target price on the stock. D. Boral Capital reiterated a “buy” rating and set a $25.00 price target on shares of Urogen Pharma in a research report on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Urogen Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Urogen Pharma Stock Performance

NASDAQ URGN opened at $25.14 on Wednesday. Urogen Pharma has a one year low of $3.42 and a one year high of $25.19. The company has a 50-day simple moving average of $18.95 and a 200-day simple moving average of $15.41. The firm has a market capitalization of $1.18 billion, a PE ratio of -7.27 and a beta of 1.06.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Thursday, November 6th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.03. The firm had revenue of $27.48 million during the quarter, compared to analyst estimates of $34.09 million. Urogen Pharma had a negative net margin of 170.59% and a negative return on equity of 97,487.15%.

Insider Activity at Urogen Pharma

In related news, General Counsel Jason Drew Smith sold 1,520 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $19.11, for a total value of $29,047.20. Following the completion of the transaction, the general counsel directly owned 43,305 shares of the company’s stock, valued at $827,558.55. This represents a 3.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Chris Degnan sold 2,203 shares of Urogen Pharma stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $16.85, for a total value of $37,120.55. Following the sale, the chief financial officer directly owned 2,280 shares in the company, valued at $38,418. The trade was a 49.14% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 4,594 shares of company stock valued at $82,813. Insiders own 4.70% of the company’s stock.

Institutional Investors Weigh In On Urogen Pharma

Several institutional investors have recently bought and sold shares of URGN. Osaic Holdings Inc. grew its position in Urogen Pharma by 491.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after buying an additional 3,070 shares in the last quarter. CWM LLC lifted its stake in shares of Urogen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company’s stock worth $58,000 after acquiring an additional 5,140 shares during the period. State of Wyoming bought a new position in shares of Urogen Pharma in the third quarter valued at approximately $66,000. Strs Ohio acquired a new position in shares of Urogen Pharma during the third quarter valued at approximately $76,000. Finally, Tower Research Capital LLC TRC raised its holdings in Urogen Pharma by 422.0% during the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after purchasing an additional 5,571 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.